Literature DB >> 10852535

The role of B cells and autoantibodies in multiple sclerosis.

J J Archelos1, M K Storch, H P Hartung.   

Abstract

A variety of cellular and humoral immunological abnormalities have been observed in multiple sclerosis (MS). In the past few years, several lines of evidence converged to imply an important role of autoreactive antibodies and B cells in the pathogenesis of MS. Recent data suggest that autoantibodies may be harmful in lesion formation but also potentially beneficial in repair. This review surveys recent advances in the concepts of generation and nature of pathogenetic autoantibodies, their potential modes of action, mechanisms of their long-term persistence, and the role of the inflamed brain tissue as a B-cell-supporting microenvironment in MS. Based on the presence of specific autoantibodies, it seems possible to define distinct MS subgroups in the near future. The therapeutic relevance of these new findings is presented.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852535

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  60 in total

Review 1.  Autonomic regulation of neuroimmunological responses: implications for multiple sclerosis.

Authors:  E M Frohman; N L Monson; A E Lovett-Racke; M K Racke
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

2.  Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 3.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

4.  Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse.

Authors:  Honghao Wang; Kai Wang; Xiaonan Zhong; Wei Qiu; Yongqiang Dai; Aimin Wu; Xueqiang Hu
Journal:  J Clin Immunol       Date:  2012-05-30       Impact factor: 8.317

5.  Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis.

Authors:  Leslie E Summers deLuca; Natalia B Pikor; Jennifer O'Leary; Georgina Galicia-Rosas; Lesley A Ward; Dustin Defreitas; Trisha M Finlay; Shalina S Ousman; Lucy R Osborne; Jennifer L Gommerman
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

6.  Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus.

Authors:  Taeg S Kim; Stanley Perlman
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues.

Authors:  Youngpyo Nam; Jong-Heon Kim; Minchul Seo; Jae-Hong Kim; Myungwon Jin; Sangmin Jeon; Jung-wan Seo; Won-Ha Lee; So Jin Bing; Youngheun Jee; Won Kee Lee; Dong Ho Park; Hyun Kook; Kyoungho Suk
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

Review 8.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

9.  Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis.

Authors:  Dorothea Buck; Eva Albrecht; Muhammad Aslam; An Goris; Natalie Hauenstein; Angela Jochim; Sabine Cepok; Verena Grummel; Bénédicte Dubois; Achim Berthele; Peter Lichtner; Christian Gieger; Juliane Winkelmann; Bernhard Hemmer
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 10.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.